Compare JBLU & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JBLU | DFTX |
|---|---|---|
| Founded | 1998 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | 2002 | N/A |
| Metric | JBLU | DFTX |
|---|---|---|
| Price | $5.00 | $24.75 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 13 | 8 |
| Target Price | $4.91 | ★ $38.50 |
| AVG Volume (30 Days) | ★ 23.9M | 2.0M |
| Earning Date | 04-28-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.83 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,062,000,000.00 | N/A |
| Revenue This Year | $12.11 | N/A |
| Revenue Next Year | $6.75 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.87 | $14.62 |
| 52 Week High | $6.46 | $26.25 |
| Indicator | JBLU | DFTX |
|---|---|---|
| Relative Strength Index (RSI) | 51.75 | 61.13 |
| Support Level | $4.90 | $16.37 |
| Resistance Level | $5.15 | $25.71 |
| Average True Range (ATR) | 0.24 | 1.48 |
| MACD | -0.01 | 0.06 |
| Stochastic Oscillator | 43.90 | 84.73 |
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It served approximately 100 destinations in the United States, the Caribbean and Latin America, Canada, and England. The company currently operates Airbus A321, Airbus A320, Airbus A321neo, and Embraer E190 aircraft types. The company has one operating segment, Air Transportation Services, which provides services in the United States, the Caribbean, Latin America, Canada, and Europe. The majority of revenue is generated from the Domestic & Canada segment.
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a best-in-class care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).